PMID- 33767992
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210327
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 11
DP  - 2021
TI  - Adverse Events Following Administration of Anti-CTLA4 Antibody Ipilimumab.
PG  - 624780
LID - 10.3389/fonc.2021.624780 [doi]
LID - 624780
AB  - Ipilimumab, a monoclonal anti-CTLA4 antibody, paved the path for promising 
      treatments, particularly in advanced forms of numerous cancers like melanoma. By 
      blockading CTLA-4, ipilimumab can abolish the higher binding affinity of B7 for 
      CTLA-4, setting CD28 free to act unlimited. This blockade can result in an 
      amplified antitumor immune response, and thereby, boosting more effective tumor 
      regression. However, this blockage can lead to diminished self-tolerance and 
      yielding autoimmune complications. The current review aims to describe adverse 
      events (AEs) following the administration of ipilimumab in different cancers as 
      every benefit comes at a cost. We will also discuss AEs in two different 
      categories, melanoma and non-melanoma, owing to the possible shining promises in 
      treating non-melanoma cancers. As the melanoma settings are more studied than 
      other cancers, it might even help predict the patterns related to the other types 
      of cancers. This similarity also might help physicians to predict adverse events 
      and correctly manage them in non-melanoma cancers using the extensive findings 
      reported in the more-studied melanoma settings. Recognizing the adverse events is 
      vital since most of the adverse events could be reverted while carefully 
      implementing guidelines. Finally, we will also describe the observed 
      effectiveness of ipilimumab in non-melanoma cancers. This effectiveness reveals 
      the importance of understanding the profile of adverse events in this group, even 
      though some have not received FDA approval yet. Further clinical trials and 
      careful systematic reviews may be required to decipher the hidden aspects of 
      therapies with ipilimumab and its related AEs.
CI  - Copyright (c) 2021 Karimi, Alilou and Mirzaei.
FAU - Karimi, Amirali
AU  - Karimi A
AD  - School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Alilou, Sanam
AU  - Alilou S
AD  - School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Mirzaei, Hamid Reza
AU  - Mirzaei HR
AD  - Department of Medical Immunology, School of Medicine, Tehran University of 
      Medical Sciences, Tehran, Iran.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210309
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC7985548
OTO - NOTNLM
OT  - Anti-CTLA4 antibody
OT  - CTLA4
OT  - adverse events
OT  - cancer immunotherapy
OT  - ipilimumab
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/03/27 06:00
MHDA- 2021/03/27 06:01
PMCR- 2021/01/01
CRDT- 2021/03/26 07:00
PHST- 2020/11/01 00:00 [received]
PHST- 2021/02/02 00:00 [accepted]
PHST- 2021/03/26 07:00 [entrez]
PHST- 2021/03/27 06:00 [pubmed]
PHST- 2021/03/27 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2021.624780 [doi]
PST - epublish
SO  - Front Oncol. 2021 Mar 9;11:624780. doi: 10.3389/fonc.2021.624780. eCollection 
      2021.